We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+17.84%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.95B
AUM Growth
+$102M
Cap. Flow
-$18.2M
Cap. Flow %
-0.46%
Top 10 Hldgs %
61.14%
Holding
68
New
17
Increased
8
Reduced
4
Closed
9
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
5.7 quarters
Top 20 Avg Time Held Equity + Options
7.2 quarters
Avg Time Held Equity only
6.4 quarters
Top 10 Avg Time Held Equity only
5.7 quarters
Top 20 Avg Time Held Equity only
7.2 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$133M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$99.5M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$83.8M
4
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$72.8M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$33.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$435M
2
ARGX icon
argenx
ARGX
+$115M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$35.6M
4
SYRE icon
Spyre Therapeutics
SYRE
+$19.1M
5
RVMD icon
Revolution Medicines
RVMD
+$3.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Miscellaneous 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$668M 16.89%
11,357,425
+184,357
+2% +$11.8M
2021 Q4
9 quarters
PRTA icon
2
Prothena Corp
PRTA
$429M
$287M 7.26%
11,584,280
– –
2018 Q4
21 quarters
ARVN icon
3
Arvinas
ARVN
$447M
$278M 7.02%
6,726,491
– –
2021 Q4
9 quarters
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.74B
$249M 6.29%
1,919,835
+1,086,928
+130% +$133M
2023 Q4
1 quarter
CRNX icon
5
DELISTED
Crinetics Pharmaceuticals
CRNX
$195M 4.92%
4,155,375
+2,142,858
+106% +$83.8M
2021 Q4
9 quarters
LKFT icon
6
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$185M 4.69%
5,756,268
– –
2021 Q3
10 quarters
ANAB icon
7
AnaptysBio
ANAB
$1.36B
$169M 4.28%
7,521,024
– –
2019 Q4
17 quarters
ZYME icon
8
Zymeworks
ZYME
$1.8B
$141M 3.58%
13,437,473
– –
2022 Q4
5 quarters
KURA icon
9
Kura Oncology
KURA
$874M
$124M 3.13%
5,806,871
– –
2015 Q4
33 quarters
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$13.7B
$122M 3.09%
1,013,952
– –
2023 Q2
3 quarters
XNCR icon
11
Xencor
XNCR
$1.75B
$118M 2.98%
5,330,416
+47,900
+0.9% +$1.03M
2018 Q4
21 quarters
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$3.21B
$111M 2.8%
5,991,479
– –
2021 Q4
9 quarters
TNGX icon
13
Tango Therapeutics
TNGX
$3.75B
$106M 2.68%
13,330,736
– –
2020 Q3
14 quarters
IMNM icon
14
Immunome
IMNM
$2.07B
$95.7M 2.42%
3,879,415
– –
2023 Q4
1 quarter
CRSP icon
15
CRISPR Therapeutics
CRSP
$4.84B
$94.7M 2.4%
+1,389,276
New +$99.5M
2024 Q1
0 quarters
MRSN icon
16
DELISTED
Mersana Therapeutics
MRSN
$86.8M 2.19%
774,588
– –
2023 Q3
2 quarters
MORF icon
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$83.9M 2.12%
2,384,384
+2,173,122
+1,029% +$72.8M
2019 Q2
19 quarters
NUVB icon
18
Nuvation Bio
NUVB
$1.66B
$69.9M 1.77%
19,209,643
– –
2021 Q1
12 quarters
NGNE icon
19
Neurogene
NGNE
$431M
$64.7M 1.64%
1,271,342
– –
2023 Q4
1 quarter
CNTA
20
DELISTED
Centessa Pharmaceuticals
CNTA
$63.5M 1.61%
5,618,779
– –
2021 Q2
11 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.17B
$47M 1.19%
3,418,068
– –
2020 Q2
15 quarters
ADAP
22
DELISTED
Adaptimmune Therapeutics
ADAP
$43.3M 1.1%
+27,404,070
New +$33.1M
2024 Q1
0 quarters
TCRX icon
23
TScan Therapeutics
TCRX
$14.7M
$39.7M 1%
5,000,000
– –
2023 Q2
3 quarters
VYGR icon
24
Voyager Therapeutics
VYGR
$132M
$36.5M 0.92%
3,917,546
+66,039
+2% +$558K
2021 Q3
10 quarters
THRD icon
25
DELISTED
Third Harmonic Bio
THRD
$30M 0.76%
3,182,444
– –
2023 Q1
4 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2024 Portfolio in Review

As of Q1 2024, EcoR1 Capital held 68 positions worth $3.95B, up 2.7% from $3.85B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q1 2024 filing shows 17 new, 8 increased, 4 reduced and 9 closed positions. Its largest new stake was CRISPR Therapeutics: 1,389,276 shares worth $94.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $435M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q1 2024 buy was CRISPR Therapeutics: 1,389,276 shares worth $94.7M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2024, an estimated $133M increase.
  • EcoR1 Capital's biggest Q1 2024 reduction was Edgewise Therapeutics, cutting an estimated $35.6M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $435M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.95B portfolio in Q1 2024.
  • EcoR1 Capital opened 17 new positions and closed 9 in Q1 2024.
  • EcoR1 Capital's portfolio value rose 2.7% quarter-over-quarter to $3.95B.

Based on EcoR1 Capital's 13F filing for Q1 2024, filed 15 May 2024.